A2AR positive allosteric modulator

Indicaton

Multiple, see therapeutic areas. GI indications also relevant.

Therapeutic indications

Type of product

Small molecule

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

Dipraglurant (mGlu5 NAM) for PD-LID

Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

Phase II started

AUP-16 (AUP1602-C)

AUP-16 is a multi-therapy live bacterial vector for chronic wounds: Diabetic Foot, Leg & Pressure Ulcers

Phase II started

Veblocema (infliximab SC)

Multiple indications in rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriasis

Marketed